



Sinclair Pharma plc

Pre-Close Period Trading Update

18 January 2006: Sinclair Pharma plc, the speciality pharma company, provides a pre-close period update ahead of its interim results announcement on Tuesday 28 March 2006.

Sinclair has continued the progress reported for the year ended 30 June 2005 with very strong revenue growth and good commercial progress. During the period, Sinclair has further developed its product portfolio, obtained EU registrations for Decapinol toothpaste and gel, launched Atopiclair in the first European market, Italy, following a successful launch in the US last year, and entered into a number of licensing agreements for its products.

Revenues for the six months to 31 December 2005 are expected to be £3.7m, significantly above the £0.8m in the same period last year. This includes a full six month revenue contribution of £1.1m from Sinclair Srl (formerly Euroderm SpA) which was acquired in January 2005.

Chairman Steve Harris said, "It is pleasing to report that the momentum in our last financial year continued throughout the first half of the current financial year. We have continued to see positive progress on all fronts as Sinclair implements its strategy of becoming an integrated international pharmaceutical company with a broad portfolio of on-market products. Sinclair remains optimistic about prospects for the full year and approaches 2006 with confidence."

Enquiries:

Sinclair Pharma plc

Dr Michael Flynn, Chief Executive Officer
Jerry Randall, Chief Financial Officer

Tel: 01483 426644

Financial Dynamics

Ben Atwell / John Gilbert

Tel: 020 7831 3113

Notes to Editors:

Sinclair Pharma plc, based in Godalming in the UK is quoted on the Alternative Investment Market (AIM) on the London Stock Exchange and has focused on the acquisition and development of niche patented pharmaceutical products in the fields of oral health and dermatology, and bringing them to the international market place via out-licensing partners. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed its products for distribution in over 40 countries around the world. www.sinclairpharma.com